Valentine Keith 4

What Happened
Valentine Keith, a director of Regentis Biomaterials Ltd. (RGNT), received a derivative award on July 9, 2026: an option grant covering 24,826 shares reported at an acquisition price of $0.00. This is an equity compensation award (transaction code A) — not a cash purchase or sale — and no shares were sold or exercised in this filing.

Key Details

• Transaction date: July 9, 2026; Form 4 filed July 13, 2026 (timely — within two business days).
• Grant size: options covering 24,826 shares; reported price $0.00 (award/grant).
• Shares owned after transaction: not disclosed in the filing.
• Approval: Board approved the grant May 28, 2026, subject to shareholder approval, which was obtained July 9, 2026.
• Vesting: vests quarterly — 1/12 vests on Aug 28, 2026, then one‑twelfth on the last day of each subsequent three‑month period, fully vesting on May 28, 2029, subject to continued service.
• Transaction type: derivative award (option grant), coded A.

Context
This report reflects an equity compensation grant to a director rather than an open‑market purchase or sale. Such awards are common as part of director pay and do not necessarily signal immediate buying or selling pressure — the options vest over three years and were not exercised or sold at grant. Filing appears timely under Section 16 rules.